NR1H4 and Cirrhosis: A 12-week, randomized, double-blind, placebo-controlled phase 2 study (NCT02943460) showed that cilofexor 30 mg and 100 mg improved markers of cholestasis and liver injury, was well tolerated, and did not exacerbate pruritus (a common side effect of FXR agonists) in patients with PSC without cirrhosis (13).